安派科美股招股说明书(2023-04-04版)

424B51ea176048-424b5anpacbio.htmPROSPECTUSSUPPLEMENT FiledPursuanttoRule424(b)(5)RegistrationNo.333-256630 PROSPECTUSSUPPLEMENT (ToProspectusdatedJune7,2021) ANPACBIO-MEDICALSCIENCECO.,LTD. 625,000AmericanDepositaryShares Pre-FundedWarrantstoPurchase125,000AmericanDepositarySharesWarrantstoPurchase750,000AmericanDepositaryShares 1,500,000AmericanDepositarySharesUnderlyingWarrantsandPre-FundedWarrants37,500AmericanDepositarySharesIssuableUponExerciseofPlacementAgentWarrants30,750,000Class‘A’ordinarysharesunderlyingADSs Weareoffering,inaregistereddirectofferingtocertaininstitutionalinvestors,anaggregateof30,750,000Class‘A’ordinarysharesofAnPacBio-MedicalScienceCo.,Ltd.(the“Company”),representedby(i)625,000AmericanDepositarySharesoftheCompany(“ADSs”)thatmaybeevidencedbyAmericanDepositaryReceipts(“ADRs”)(eachADSrepresents20Class‘A’ordinaryshares),(ii)125,000pre-fundedwarrantstopurchaseuptoanaggregateof125,000ofourADSstocertaininvestorswhosepurchaseofADSsinthisofferingwouldotherwiseresultinsuchinvestor,togetherwithitsaffiliatesandcertainrelatedparties,beneficiallyowningmorethan4.99%(or,attheelectionofsuchinvestor,9.99%)ofouroutstandingADSsimmediatelyfollowingtheconsummationofthisoffering(the“Pre-FundedWarrants”),(iii)warrantstopurchaseuptoanaggregateof750,000ofourADSs(the“Warrants”),and(iv)37,500ADSsissuableuponexerciseofwarrantsissuedtotheplacementagentfortheoffering(the“PlacementAgent’sWarrants”).Suchsecuritiesarebeingissuedpursuanttothisprospectussupplement,theaccompanyingbaseprospectus,thatcertainsecuritiespurchaseagreement,datedMarch31,2023,byandamongtheCompanyandtheinstitutionalinvestorssignatorythereto(the“SecuritiesPurchaseAgreement”)andthatcertainplacementagencyagreement,datedMarch31,2023,byandbetweentheCompanyandUnivestSecurities,LLC(“Univest”orthe“placementagent”).ThisprospectussupplementalsocoverstheADSsissuablefromtimetotimeuponexerciseofthePre-FundedWarrants,theWarrantsandthePlacementAgent’sWarrants,andtheClassAordinarysharesunderlyingtheADSsissuablepursuanttotheSecuritiesPurchaseAgreementandallsuchwarrants.See“PlanofDistribution–PlacementAgent’sWarrants”beginningonpageS-25formoreinformationregardingthePlacementAgent’sWarrants. OurADSsarelistedontheNASDAQCapitalMarketunderthesymbol“ANPC”.OnMarch31,2023,theclosingpriceofanADSontheNasdaqCapitalMarketwasUS$4.24.EachADSandPre-FundedWarrantofferedherebyisbeingsoldtogetherwithaWarrantandeachADSandPre-FundedWarrantisimmediatelyseparablefromtheaccompanyingWarrant,respectively,andwillbeissuedseparatelyfromsuchWarrant.EachWarrantisexercisableforoneofourADSsatanexercisepriceof$4.00perADS.TheWarrantsareimmediatelyexercisableandwillexpirefiveyearsfromtheoriginalissuancedate.ThepurchasepriceofeachPre-FundedWarrantisequaltothepurchasepriceperADS,minus$0.0001,andtheexercisepriceofeachPre-FundedWarrantis$0.0001pershare. ThereisnoestablishedtradingmarketfortheWarrantsorPre-FundedWarrants,andwedonotexpectamarkettodevelop.Inaddition,wedonotintendtoapplyforthelistingofsuchwarrantsonanynationalsecuritiesexchangeorothertradingmarket.Withoutanactivetradingmarket,theliquidityofsuchwarrantswillbelimited. Asofthedateofthisprospectussupplement,theaggregatemarketvalueofouroutstandingordinarysharesheldbynon-affiliateswasapproximatelyUS$45.9millionbasedon112,964,393issuedandoutstandingClass“A’ordinaryshares,ofwhich88,984,233Class“A’ordinarysharesareheldbynon-affiliates,andapersharepriceof$0.516($10.32perADS),whichwasthehighestclosingpriceoverthelastsixtydaysontheNasdaqCapitalMarketofour ADSs.Asofthedateofthisprospectussupplement,pursuanttoGeneralInstructionI.B.5.ofFormF-3,theCompanyhasnotconductedanytransactionsinthelast12months.Weareauthorizedtoissueamaximumof2,400,000,000Class‘A’ordinaryshareswithaparvalueofUS$0.01eachand30,000,000Class‘B’ordinaryshareswithaparvalueofUS$0.01each.HoldersofClass‘A’ordinarysharesandClass‘B’ordinaryshareshavethesamerights,exceptforvotingandconversionrights.EachClass‘A’ordinaryshareisentitledtoonevote;andeachClass‘B’ordinaryshareisentitledtotenvotesandisconvertibleintooneClass‘A’ordinaryshareatanytimebytheholderthereof.Class‘A’ordinarysharesarenotconvertibleintoClass‘B’ordinarysharesunderanycircumstances.AsofMarch26,2023wehad109,391,293Class‘A’ordinarysharesissuedandoutstandingand3,573,100Class‘B’ordinarysharesissuedandoutstanding.ForamoredetaileddescriptionoftheADSs,Pre-FundedWarrantsandWarrantsofferedhereby,seethesectionentitled“DescriptionofSecuritiesWeAreOffering”beginningonpageS-16. TheADSsofferedinthisprospectusrepresenttheClass‘A’ordinarysharesoftheCompany,aBritishVirginIslandscompany.Weareaholdingcompanywithnomaterialoperationsofourown,andconductsubstantiallyallofouroperationsthroughourwholly-ownedsubsidiariesinthePeople’sRepublicofChina(the“PRC”)andinthe U.S.Ourcompanystructureinvolvesuniqueriskstoinvestors.Chineseregulatoryauthoritiescoulddisallowouroperatingstructure,whichwouldlikelyresultinamaterialchangeinouroperationsand/orthevalueofourADSsorourothersecurities,includingthatitcouldcausethevalueofsuchsecuritiestosignificantlydeclineorb